Urofollitropin refers to a purified variety of a hormone known as follicle-stimulating hormone (FSH), which is vital for the formation of follicles, or eggs, that are made by the female ovaries.
Urofollitropin is combined with other medications to cure infertility in females with FSH deficiency. It also helps the ovaries produce many eggs that are used in “in-vitro” fertilization.
Urofollitropin alone cannot cause ovulation (production of eggs by the ovaries); other fertility medicines are needed to stimulate this.
You shouldn’t use Urofollitropin if you have abnormal vaginal bleeding, primary ovary failure, uncontrolled adrenal or thyroid gland disorders, breast cancer, ovarian cyst, ovarian or uterine cancer, pituitary gland tumor, or infertility that’s not due to lack of ovulation.
Don’t use this medication if you’re pregnant.
Don’t use Urofollitropin, abstain from sex, and call your physician immediately if you experience any of these symptoms:
Your doctor will perform a pelvic exam and some blood tests to ensure you don’t have problems that would prevent safe use of Urofollitropin.
Also have your man’s fertility checked before you commence treatment with Urofollitropin.
To ensure Urofollitropin is safe to use, let your doctor know if you have had asthma, or stomach surgery before, ovarian cyst (torsion/twisting of ovary), or risk factors for clots (such as heart disease, diabetes, coronary artery disease, smoking, being overweight, or coronary artery disease running in your family).
Using Urofollitropin may increase your odds of a multiple pregnancy (such as twins, triplets, quadruplets, and so on). Any multiple pregnancy is usually very risky for the babies and the mother. Follow your physician’s instruction regarding the special care you might need during pregnancy.
Urofollitropin can also increase the risk of miscarriage, tubal pregnancy, stillbirth, birth defects, fever after childbirth, or premature labor. Talk to your doctor if you’re worried about these risks.
Urofollitropin can also increase the risk of uterine cancer. Find out your specific risk from your doctor. Report any abnormal vaginal bleeding immediately.
While Urofollitropin may help you get pregnant, it can cause birth defects or harm the unborn child. Don’t take this medicine if you’re pregnant. Let your doctor know right away if you get pregnant during treatment.
It’s unclear whether Urofollitropin could be bad for a nursing baby or if it gets into breast milk. Do not breastfeed while taking this medicine.
Urofollitropin treats these conditions in women:
Many medicines can bring about side effects. Side effects may be severe or mild, temporary or permanent.
The following side effects aren’t experienced by everybody who uses Urofollitropin. If you’re worried about the side effects, talk to your doctor about the benefits and risks of this medicine.
At least 1% of people using Urofollitropin have reported the side effects cataloged below. Many of them can be controlled, and some can gradually disappear on their own.
While most of the side effects mentioned below happen less often, they could result in serious complications if you don’t get medical attention.
Some people can experience side effects that are different to those listed. Talk to your physician if you have any unusual symptom that makes you worried while taking Urofollitropin.
Follow all instructions on your prescription. Do not take Urofollitropin in smaller or larger quantities for longer than prescribed.
Urofollitropin is injected into a muscle or under the skin. Your doctor may show you how to inject yourself at home. Don’t self-inject Urofollitropin if you don’t know how to do it and properly get rid of used syringes and needles.
Urofollitropin comes with instructions for patients for effective and safe use. Follow these instructions carefully. If you’ve got any questions, ask your pharmacist or doctor.
Urofollitropin is medication that’s in the form of a powder that you must mix with a liquid before use. If you’re self-injecting at home, make sure you know how to mix and store Urofollitropin properly.
After mixing, swirl the medicine gently. Don’t shake the medicine bottle or it’ll be ruined. Don’t prepare your dose if you aren’t ready to take an injection. Don’t use Urofollitropin if it’s cloudy, has particles, and has changed colors. Get new medicine from your pharmacist.
After taking the injection, dispose of any remains of the medication that’s not used immediately. Don’t keep it for future use.
To achieve the best results from Urofollitropin or other fertility treatments, stick to your physician’s instructions very carefully.
Use a disposable syringe and needle just once. Follow any local or state laws about disposal of used syringes and needles. Use a puncture-proof disposal bin (ask your pharmacist to help you find one and also ask how it’s disposed of). Keep this container far away from kids and pets.
To ensure Urofollitropin is effective, have ultrasound exams and blood tests more often. You should also record your daily temperature on a chart.
Infertility is usually treated with a mix of drugs. Take all medicines as instructed by your physician. Read the patient instructions or medicine guide given with each medicine. Don’t change your medication schedule or doses without consulting your doctor.
If you miss a dose, call your doctor for further instructions.
If you overdose, seek medical attention right away. There are no known symptoms of Urofollitropin overdose.
While using Urofollitropin, there are some things you should avoid. Make sure to follow your doctor’s directions about any restrictions concerning food, drinks, or activity.
Let your pharmacist or doctor know about all over-the-counter (non-prescription), prescription, and herbal medicines you’re using. Also let them know about any supplements you’re taking. As street drugs, caffeine, nicotine in cigarettes, and alcohol can affect the work of many medicines, be sure to let your pharmacist or doctor know if you’re using any of them. Depending on your circumstances, your physician may ask you to:
When two medicines interact, it doesn’t necessarily mean that you cease using one of them. In general, interactions are managed or controlled by close monitoring. Talk to your physician about how drug interactions should be managed or how they are managed.
Urofollitropin should not be taken by any patient who has a history of hypersensitivity to the drug.
It’s been argued that using fertility drugs might heighten the risk of some cancers in women. Several case reports and a number of observational studies fueled the theory that the high number of ovulatory eggs and/or high levels of estrogen and gonadotropin caused by infertility treatment can induce the development of ovarian carcinoma or breast carcinoma. However, it should be noted that infertility on its own is a risk for either ovarian or breast cancer.
In addition, case reports rarely take into account other independent confounding factors like family history or delay in parenthood. In one long study done on 1,197 infertile women, it was found that the risk of breast or ovarian cancer wasn’t considerably raised in the groups getting fertility treatments against those not receiving treatments. In particular, the rate of breast cancer was not much different from either group against the general population of females. Although more studies are required, current data doesn’t support the link between the intake of fertility treatments and increased risk of cancer.
Urofollitropin must not be taken to treat any cause of infertility except lack of ovulation.
Children should not take Urofollitropin.
All patients should be careful when operating machinery or driving while using Urofollitropin. This medicine can cause dizziness.
Patients with asthma should use Urofollitropin carefully. The medicine can make the condition worse.
Urofollitropin shouldn’t be used by patients with unchecked adrenal insufficiency, unchecked thyroid problem, or intracranial lesion like a sex-hormone-reliant pituitary adenoma. These conditions can be exacerbated by increasing sex hormone levels.
Urofollitropin should not be used by men with normal levels of serum gonadotropin, which is a sign of normal pituitary function. It should also not be used by those with primary testicular dysfunction (indicated by high levels of serum gonadotropin).In addition, Urofollitropin shouldn’t be taken to treat infertility except that which is caused by hypogonadotropic hypogonadism.
Urofollitropin shouldn’t be taken by patients with primary ovarian disease because it’s not effective in such patients.
Patients with unexplained vaginal bleeding or dysfunctional uterine bleeding should not use Urofollitropin. This can be a sign of the presence of carcinoma or endometrial hyperplasia, which can be worsened by increased levels of estrogen serum as a result of ovulation. Before using this medicine, make sure to rule out any potential for uterine neoplasms. Endometrial growth can be induced by fertility treatments, so, patients with endometriosis or leiomyamata (fibroids) should use Urofollitropin carefully.
Clinical studies carried out on Urofollitropin for infertility treatment in females usually don’t include senior women. Elderly women who are going through ART (assisted reproductive technology) procedures should use this medicine cautiously.
Before a woman starts using Urofollitropin, she should undergo a full gynecologic test and endocrine exam. Save for patients under the ART programs, this must include an exam to check for tubal pathology. Patients with an underlying ovarian cyst that’s not caused by PCOS (polycystic ovarian syndrome) or ovarian enlargement should not take Urofollitropin. Urofollitropin treatment should not be started until the cause of the enlargement or cyst has been identified and the size of the ovary is back to normal.
All female patients receiving Urofollitropin therapy should report symptoms of enlarged ovaries, such as pelvic pain or abdominal pain, vomiting, nausea, weight gain, or ascites (distention and fluid in the abdomen) immediately. The current program of fertility treatments should be stopped if ovarian hyperstimulation syndrome or ovarian enlargement occurs or ovarian cyst forms.
Maximal ovarian enlargement might not be evident till several days after discontinuing fertility treatment. Sex should be shunned to limit the risk of trauma. HCG should not be administered for these patients or those with signs or symptoms of unusual ovarian growth on the final day of Urofollitropin use. However, not using HCG doesn’t guarantee that ovarian hyperstimulation syndrome won’t occur. Fertility treatment shouldn’t be resumed until the size of ovaries is back to normal. Thorough pelvic tests, such as pelvic ultrasounds, must be repeated in female patients before and during each fertility medicine cycle. Some people with PCOS (polycystic ovary syndrome) are hypersensitive to gonadotropins and can have an unusually strong reaction to ovarian hyperstimulation therapies.
Urofollitropin is classified by FDA in category X in terms of pregnancy risk and must not be taken after conception has happened. Before Urofollitropin is administered with other fertility treatments, pregnancy must be ruled out. Urofollitropin is not needed and should be avoided during pregnancy. Patients who conceive are more likely to experience protracted and more severe ovarian hyperstimulation syndrome after undergoing female sex hormone therapy.
In addition to possible effects on the unborn child, such as spontaneous abortion and congenital malformation, therapies using female sex hormones inherently heighten the risk of multiple pregnancies and the risks attached to them.
It’s not clear whether Urofollitropin gets into breast milk. Since many drugs end up in breast milk and due to the possibility of severe adverse reactions in a nursing baby as a result of Urofollitropin use, one should decide whether to discontinue the medicine or stop breastfeeding, taking into consideration the value of the medicine to the mother.
In rare cases, thromboembolic incidents have been reported by women receiving medicines for fertility programs. Patients whose family has a history of thrombophlebitis or who have the condition themselves should be extremely cautious when using Urofollitropin. Patients with serious obesity should be very careful too. Such patients may have a heightened risk of arterial or venous thromboembolic incidents after or during treatment with gonadotropins. Men using Urofollitropin do not need to heed this warning.
Drinking alcoholic drinks, including intoxication by ethanol, and smoking cigarettes are two lifestyle habits that may reduce fertility or make fertility treatments less effective in some men and/or women. Patients should avoid consuming too much alcohol or tobacco while undergoing fertility treatment with Urofollitropin.
Consult your local refuse disposal service or pharmacist for more information about how to discard the medicine safely
Urofollitropin is an effective prescription medicine used to treat female infertility. It belongs to a class of drugs known as infertility agents, which work to induce ovulation or the production of eggs.
This medicine is available as an injectable that is injected just below the skin or directly into an intravenous muscle by a doctor or other medical professional.
Some of the common Urofollitropin side effects include headache, abdominal swelling, abdominal cramps, back pain, vaginal discharge, constipation, hot flashes, and mild diarrhea.
Urofollitropin is only available with a doctor’s prescription.